Targeting Cancer, Sparing Patients.

New drugs called antibody-drug conjugates (ADCs) are being hailed as a breakthrough in cancer treatment. These drugs, such as Enhertu and T-DM1, target cancer cells specifically, sparing healthy cells and reducing the severe side effects associated with traditional chemotherapy. By combining an antibody that homes in on cancer cells with a toxic drug, ADCs deliver a tumor-destroying payload. While there are still challenges to overcome, ADCs have shown promising results in extending the lives of patients with breast cancer and other types of cancer, offering new possibilities for more effective and less toxic cancer treatments. [Extracted from the article]